menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Cell Therapy Group Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Cell Therapy Group Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Cell Therapy Group Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Cell Therapy Group Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sunkaky Medical Cooperation","sponsor":"Abinopharm Inc | Aba Chemicals Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Sunkaky Medical Cooperation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunkaky Medical Cooperation \/ Abinopharm Inc | Aba Chemicals Co Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Sunkaky Medical Cooperation \/ Abinopharm Inc | Aba Chemicals Co Ltd"},{"orgOrder":0,"company":"Seneque SA","sponsor":"CEN Nutriment | Centre d'Expertise de la Performance | LGD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Seneque SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seneque SA \/ CEN Nutriment | Centre d'Expertise de la Performance | LGD","highestDevelopmentStatusID":"1","companyTruncated":"Seneque SA \/ CEN Nutriment | Centre d'Expertise de la Performance | LGD"},{"orgOrder":0,"company":"Seneque SA","sponsor":"CEN Biotech | LGD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Seneque SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seneque SA \/ CEN Biotech | LGD","highestDevelopmentStatusID":"1","companyTruncated":"Seneque SA \/ CEN Biotech | LGD"},{"orgOrder":0,"company":"Seneque SA","sponsor":"Dicentra Inc. | LGD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Seneque SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seneque SA \/ Dicentra Inc. | LGD","highestDevelopmentStatusID":"1","companyTruncated":"Seneque SA \/ Dicentra Inc. | LGD"},{"orgOrder":0,"company":"Abinopharm Inc","sponsor":"Prorelix Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abinopharm Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abinopharm Inc \/ Prorelix Research","highestDevelopmentStatusID":"1","companyTruncated":"Abinopharm Inc \/ Prorelix Research"},{"orgOrder":0,"company":"TriHealth","sponsor":"DoNotAge.org","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriHealth \/ DoNotAge.org","highestDevelopmentStatusID":"1","companyTruncated":"TriHealth \/ DoNotAge.org"},{"orgOrder":0,"company":"Metro International Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Metro International Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metro International Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Metro International Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Cell Therapy Group Co.,Ltd","sponsor":"Shanghai Mengchao Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Shanghai Cell Therapy Group Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Cell Therapy Group Co.,Ltd \/ Shanghai Mengchao Cancer Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Cell Therapy Group Co.,Ltd \/ Shanghai Mengchao Cancer Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals for Nicotinamide Mononucleotide

    Menu

    Nicotinamide Mononucleotide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TriHealth

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            TriHealth

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : DoNotAge.org

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure

                            Details : Nicotinamide Mononucleotide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 21, 2025

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : DoNotAge.org

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Metro International Biotech

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            Metro International Biotech

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tracing the Metabolic Flux of Orally Administered NAD+ Precursors

                            Details : Nicotinamide Mononucleotide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2025

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sunkaky Medical Cooperation

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            Sunkaky Medical Cooperation

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Undisclosed

                            Sponsor : Abinopharm Inc | Aba Chemicals Co Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigate the Efficacy of Using NMN to Improve Embryo Development Capacity.

                            Details : Nicotinamide Mononucleotide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Infertility, Female.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 08, 2024

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Undisclosed

                            Sponsor : Abinopharm Inc | Aba Chemicals Co Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Shanghai Cell Therapy Group Co.,Ltd

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            Shanghai Cell Therapy Group Co.,Ltd

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Exploratory Study on the Biological Function of Dendritic Cells In Vivo Supported by Nicotinamide Mononucl...

                            Details : Nicotinamide Mononucleotide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 13, 2023

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shanghai Cell Therapy Group Co.,Ltd

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            Shanghai Cell Therapy Group Co.,Ltd

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Shanghai Mengchao Cancer Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Exploratory Study on the Nicotinamide Mononucleotide (Vital NAD ) to Promote the Rejuvenation of the Perip...

                            Details : NMN is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 09, 2023

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Shanghai Mengchao Cancer Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Seneque SA

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            Seneque SA

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Dicentra Inc. | LGD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.

                            Details : Nicotinamide Mononucleotide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 02, 2021

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Dicentra Inc. | LGD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Seneque SA

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            Seneque SA

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : CEN Biotech | LGD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults

                            Details : Nicotinamide Mononucleotide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 28, 2021

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : CEN Biotech | LGD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Abinopharm Inc

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            Abinopharm Inc

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Prorelix Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years)...

                            Details : Nicotinamide Mononucleotide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Aging.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 30, 2021

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Prorelix Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Seneque SA

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            Seneque SA

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : CEN Nutriment | Centre d'Expertise de la Performance | LGD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity

                            Details : Nicotinamide Mononucleotide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 11, 2020

                            Lead Product(s) : Nicotinamide Mononucleotide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : CEN Nutriment | Centre d'Expertise de la Performance | LGD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth